Table 1.
Clinical parameters of the sample during the study
| Variable | Value |
|---|---|
| Age (yr) | 43.2 ± 18.3 |
| Sex, female | 38 (60.3) |
| Marital status (married) | 29 (46.0) |
| Education | |
| High school or higher | 57 (90.4) |
| Family history | 0 (0.0) |
| General national health insurance | 50 (79.3) |
| Comorbidity | 11 (17.4) |
| Onset age (yr) | 39.4 ± 16.6 |
| History of admission | 2 (3.2) |
| Number of previous MDD episode | 2.8 ± 1.9 |
| Duration of current treatment (mo) | 6.0 ± 3.7 |
| MADRS at baseline/endpoint | 16.0 ± 4.3/14.5 ± 5.4 |
| CGI-CB at baseline/endpoint | 6.6 ± 2.8/5.9 ± 3.0 |
| VAS at baseline/endpoint | 6.4 ± 0.6/6.5 ± 1.0 |
| Proportion of the patients on CGI-CB 1−4 at baseline/endpoint | 15 (23.8)/24 (38.1) |
| Antidepressants | |
| Escitalopram | 16 (25.3) |
| Fluoxetine | 3 (4.7) |
| Paroxetine | 5 (7.9) |
| Sertraline | 3 (4.7) |
| Mirtazapine | 2 (3.1) |
| Venlafaxine | 23 (36.5) |
| Others | 11 (17.4) |
| Antianxiety drugsa | |
| Alprazolam | 29 (46.0) |
| Lorazepam | 4 (6.3) |
| Clonazepam | 16 (25.3) |
| Others | 5 (7.9) |
Values are presented as mean ± standard deviation or number (%).
MDD, major depressive disorder; MADRS, Montgomery and Asberg Depression Rating Scale; CGI-CB, Clinical Global Impression- Clinical Benefit; VAS, visual analog scale.
aOne patient had combined benzodiazepine treatment.